EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three-decade commitment to protect patients. They eliminate trade barriers on innovative medicines. EFPIA warns of substantial negative impacts. These impacts affect patient access, research funding, and global supply chains. Consequently, EFPIA is calling for exemptions for innovative medicines. It is also seeking a Strategic Sector Dialogue with European policymakers.
Key Insights
The most significant concern centers on the €18 billion estimated cost of 15% tariffs. This cost is a major financial burden. EU pharmaceutical exports to the US totaled €120 billion in 2024. This figure drastically exceeds automotive exports of €38.9 billion. It underscores pharmaceuticals as a critical trade sector.
EFPIA’s position reflects broader industry anxiety. There is worry about supply chain disruption and R&D divestment. The organization warns that tariffs will compel companies to absorb unsustainable costs. This is due to existing long-term pricing agreements. It could divert billions of euros away from medical research.
The statement reveals a strategic shift in pharmaceutical trade policy. The agreement caps pharmaceutical tariffs at 15% for EU drugs. EFPIA emphasizes this departs from the historical precedent of tariff-free trade.
Implications for Health Economics and Outcomes Research
The potentialtariffs carry profound implications. Patient access and health equity concerns are paramount. Tariff-induced cost increases could exacerbate existing disparities.
Research and development funding allocation is another critical concern. The diversion of funds could impact the pipeline of innovative treatments. This is relevant given EFPIA’s documentation of medicine delays.
The competitiveness of European research infrastructure may be compromised. This could affect health technology assessment capacity. EFPIA advocates for collaboration in relative efficacy assessments.
Long-term sustainability of healthcare systems faces pressure. Companies may have to absorb costs initially. This could lead to pricing pressures on national health budgets.
